Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Randomised, Multicentre, Open-label Study Evaluating the Effectiveness of Switching to Two-monthly Long-acting Injectable Cabotegravir and Rilpivirine From First-line Oral Antiretroviral Therapy in HIV-1 Positive Virologically Suppressed Adults With a History of, or at Risk of, Sub-optimal HIV Control in Sub-Saharan Africa

NCT05546242 is registered in ClinicalTrials.gov with MRC/UVRI and LSHTM Uganda Research Unit as lead sponsor.

NCT NCT05546242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05546242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Randomised, Multicentre, Open-label Study Evaluating the Effectiveness of Switching to Two-monthly Long-acting Injectable Cabotegravir and Rilpivirine From First-line Oral Antiretroviral Therapy in HIV-1 Positive Virologically Suppressed Adults With a History of, or at Risk of, Sub-optimal HIV Control in Sub-Saharan Africa
Lead sponsor
MRC/UVRI and LSHTM Uganda Research Unit
Phase
Phase 3
Overall status
Completed
Start date
December 8, 2022
Completion date
March 20, 2026
Enrollment
540 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection